An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.

OBJECTIVE

No head-to-head trials have compared the efficacy of zanubrutinib versus ibrutinib in relapsed/refractory mantle-cell lymphoma (R/R MCL).

METHODS

Following a systematic literature review, individual patient data from trials of zanubrutinib (n = 118) and aggregate data from a pooled analysis of ibrutinib trials (n = 370) were analyzed using an unanchored matching-adjusted indirect comparison (MAIC).

RESULTS

After matching selected covariates, statistically significant differences were observed with zanubrutinib versus ibrutinib for progression-free survival (hazard ratio [HR] = 0.63; 95% confidence interval [CI] 0.46-0.87, p = .0044) and overall survival (HR, 0.46; 95% CI 0.30-0.71, p = .0005).

CONCLUSION

These MAIC analyses demonstrate that zanubrutinib may be more effective than ibrutinib at delaying disease progression and death in R/R MCL.